priors.science/reviews/severe-asthma-management

Severe Asthma Management

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked
115primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 9 Likely · 3 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Dupilumab reduces exacerbations and improves lung function in type 2-high asthmaDupilumabEstablished92%7
Anti-IL-5 agents reduce exacerbations in severe eosinophilic asthmaAnti Il5Established92%9
Anti-IL-5 therapy enables oral corticosteroid dose reduction in corticosteroid-dependent severe eosinophilic asthmaAnti Il5Established91%8
Omalizumab (anti-IgE) reduces exacerbations and healthcare visits in severe allergic asthmaOmalizumabEstablished91%7
Tezepelumab reduces exacerbations across type 2-high and type 2-low severe asthmaTezepelumabLikely78%8
Dupilumab enables oral corticosteroid elimination in corticosteroid-dependent severe asthmaDupilumabLikely77%7
Fractional exhaled nitric oxide identifies type 2 inflammation and predicts response to dupilumab and tezepelumabBiomarkersLikely76%8
Blood eosinophils and exhaled nitric oxide fluctuate on inhaled corticosteroids, complicating biologic eligibilityBiomarkersLikely76%8
Blood eosinophil count predicts clinical response to anti-IL-5 therapy in severe asthmaAnti Il5Likely76%8
Total IgE and allergen sensitisation guide omalizumab eligibility and dosingOmalizumabLikely76%8
Biologic discontinuation after sustained remission causes loss of asthma control in most patientsStrategyLikely76%8
Tezepelumab reduces blood eosinophils, exhaled nitric oxide, and IgE, confirming broad type 2 pathway suppressionTezepelumabLikely76%8
Real-world biologic effectiveness matches trial outcomes with biomarker-based selectionStrategyLikely75%8
Itepekimab (anti-IL-33) reduces exacerbations in moderate-to-severe asthma without dupilumabTezepelumabUncertain51%8
Composite biomarkers (eosinophils, exhaled nitric oxide, IgE, sensitisation) guide biologic selection in severe asthmaBiomarkersUncertain50%8
Biologic therapy achieves asthma remission in 20-30% of severe asthma patientsStrategyUncertain50%7
Track Severe Asthma Management.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.